发明名称 Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor through administration of a pyrophosphate analog
摘要 Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor by administering a pyrophosphate analog. Methods and compositions for protecting a pharmacological agent in a formulation, comprising combining the pharmacological agent with at least one pyrophosphate analog. Methods and compositions for increasing the efficacy of a neurologic agent by administering at least one pyrophosphate analog. Methods and compositions for increasing the efficacy of an agent that neither directly nor indirectly affects a muscarinic receptor by administering at least one pyrophosphate analog.
申请公布号 US9072756(B2) 申请公布日期 2015.07.07
申请号 US200511220222 申请日期 2005.09.06
申请人 HealthPartners Research Foundation 发明人 Frey, II William H.;Fawcett John Randall
分类号 A61K31/70;A61K31/6615;A61K31/352;A61K31/409;A61K31/66;A61K31/661;A61K31/662;A61K31/663;A61K31/7072;A61K31/7076;A61K31/708;A61K31/7084;A61K31/7105;A61K45/06 主分类号 A61K31/70
代理机构 Winthrop & Weinstine, P.A. 代理人 Winthrop & Weinstine, P.A.
主权项 1. A method for increasing the efficacy of an agent that inhibits acetylcholinesterase in a subject suffering from Alzheimer's disease, comprising: delivering an effective amount of pamidronate to a subject suffering from Alzheimer's disease that is concurrently receiving, has recently received, or will soon receive an agent that inhibits acetylcholinesterase; and increasing the efficacy of the agent that inhibits acetylcholinesterase in the subject in need thereof; wherein the effective amount of pamidronate is intranasally administered to the upper one third of the subject's nasal cavity, thereby enabling the pamidronate to bypass the subject's blood-brain barrier.
地址 Bloomington MN US